Related Experiment Video

Updated: Mar 29, 2026

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals
06:46

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

18.0K

The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with

Theodoros Kelesidis1, Vasiliki Papakonstantinou2, Paraskevi Detopoulou3

  • 1David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

AIDS Reviews
|December 1, 2015
PubMed

Insights

Platelet-activating factor (PAF) may link HIV-1 infection, inflammation, and cardiovascular disease. Targeting PAF could improve health outcomes for HIV-1 patients.

Area of Science:

  • Immunology
  • Cardiovascular Medicine
  • Virology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death in treated HIV-1 patients.
  • The exact mechanisms driving CVD pathogenesis in HIV-1 are not fully understood.
  • Platelet-activating factor (PAF) is implicated in inflammation and cardiovascular disease.

Purpose of the Study:

  • To review the role of the PAF pathway in HIV-1 immunopathogenesis.
  • To explore the link between HIV-1, immune dysregulation, inflammation, and PAF.
  • To identify potential therapeutic strategies targeting PAF for HIV-1 comorbidities.

Main Methods:

  • Literature review examining the interplay of HIV-1, immune responses, and PAF.
  • Analysis of existing scientific evidence on PAF pathway involvement in HIV-1.
  • Exploration of potential therapeutic interventions modulating PAF activity.

Main Results:

  • The PAF pathway may be a key mediator connecting HIV-1 infection, systemic inflammation, and immune activation.
  • Cross-talk between HIV-1, immune dysregulation, and PAF perturbations contributes to chronic HIV-related comorbidities.
  • PAF's role is crucial in the pathogenesis of CVD and HIV-associated neurocognitive disorders.

Conclusions:

  • Understanding PAF's role in HIV-1 infection is critical for elucidating disease mechanisms.
  • Targeting PAF activity through diet or PAF inhibitors may offer novel therapeutic avenues.
  • Modulating PAF could improve the prognosis and management of cardiovascular complications in HIV-1 patients.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.0K
Peptide-based Identification of Functional Motifs and their Binding Partners14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

13.1K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K
Inflammation01:38

Inflammation

Overview
64.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.2K